All In Biotech

Drug Trial Radar · NCT07704099

Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

A Multicenter, Phase 2, Open-Label Study Evaluating the Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Sep 25, 2026

Primary completion

Aug 26, 2028

Study completion Sep 23, 2028

Sponsor

Lead sponsor
Keros Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • KER-065Drug

    KER-065 will be administered subcutaneously (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs and serious adverse events (SAEs)Time frame: Up to approximately 14 months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • LTD TIM - Tbilisi Institute of Medicine

    Tbilisi, Georgia · Not yet recruiting

  • Institute of Neurology and Neuropsychology LTD

    Tbilisi, Georgia · Not yet recruiting

  • Optimal Clinical Trials

    Auckland, North Island, New Zealand · Recruiting

  • NZCR-Christchurch

    Christchurch, South Island, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.